ASIC3 and psoriasis: AAV-ASIC3-shRNA markedly reduced splenomegaly in the psoriasis model (Supplementary Fig. 3f) and mitigated skin inflammation and keratinocyte hyperproliferation, as demonstrated by histopathologic assessment (Supplementary Fig. 3g–j).